Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Open accessThe DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index; 3 of the 39 sources its claims cite were checked for support.
Abstract
BACKGROUND: Fatigue is a highly prevalent and disabling symptom in cancer survivors. Although many measures have been developed to assess survivors' fatigue, their ability to accurately capture change following intervention has rarely been assessed in post-treatment survivors. Ultra-brief fatigue measures are preferable in clinical practice but have limited evidence supporting their use with cancer survivors. We examined the psychometric properties of four Fatigue Symptom Inventory (FSI) measures, including the new FSI-3, in cancer survivors. Examined properties included responsiveness to change and minimally important differences (MIDs). METHODS: We analyzed data from three randomized controlled trials with post-treatment cancer survivors (N = 328). Responsiveness to change was evaluated by comparing standardized response means for survivors who reported their fatigue as being better, the same, or worse at 2-3 months. Responsiveness to intervention was assessed via effect sizes, and MIDs were estimated by using several methods. We also computed area under the curve (AUC) values to assess FSI measures' discriminative accuracy compared to an established cut-point. RESULTS: All FSI measures differentiated survivors who reported improvement at 2-3 months from those with stable fatigue, but did not uniformly differentiate worsening fatigue from stable fatigue. Measures showed similar levels of responsiveness to intervention, and MIDs ranged from 0.29 to 2.20 across FSI measures. AUC analyses supported the measures' ability to detect significant fatigue. CONCLUSIONS: Four FSI scales show similar responsiveness to change, and estimated MIDs can inform assessment of meaningful change in fatigue. The FSI-3 shows promise as an ultra-brief fatigue measure for survivors.
Overview
CoChat Summary
## TL;DR
This study evaluated four Fatigue Symptom Inventory (FSI) measures, including a new ultra-brief FSI-3, in 328 post-treatment cancer survivors from three randomized controlled trials. The FSI measures showed similar responsiveness to change, and the FSI-3 showed promise with a preliminary cut-point of mean score ≥ 5.
## Key findings
- In three RCTs with post-treatment cancer survivors (N = 328), all FSI measures differentiated survivors who reported improvement at 2–3 months from those with stable fatigue, but they did not uniformly differentiate worsening fatigue from stable fatigue.
- For responsiveness to change, the BEAT Cancer trial showed significant differentiation for all FSI measures between Worse and Same groups and between Better and Same groups, with SRMs ranging from 0.69 to 0.95 and from -0.78 to -0.96, respectively; in the MBSR trials, all FSI measures significantly differentiated Better from Same groups with SRMs from -0.88 to -1.13, but not Worse from Same.
- MID estimates on the 0 to 10 FSI scales ranged from 0.90 to 1.69 using the global change anchor; coefficient of repeatability ranged from 1.10 to 2.20; 0.5 SD ranged from 0.73 to 1.10; and 2 SEM ranged from 0.79 to 1.59.
- AUC values for distinguishing clinically significant fatigue at baseline ranged from 0.64 to 0.88, with 7 of 8 values being 0.74 or higher; for the FSI-3, a preliminary cut-point of mean score ≥ 5 gave sensitivity 0.77 and specificity 0.87.
## Methods
- Data came from three randomized controlled trials with post-treatment cancer survivors (N = 328): two mindfulness-based stress reduction (MBSR) trials and the BEAT Cancer physical activity trial; baseline and first follow-up data were used.
- The paper compared four fatigue measures: FSI severity, FSI interference, FSI total, and the derived 3-item FSI-3; SF-36 Vitality served as the anchor for responsiveness and ROC analyses.
- Main analyses included standardized response means (SRMs), between-group effect sizes, MID estimation using several methods, and ROC/AUC analyses relative to an SF-36 Vitality cut-point of ≤ 45.
## Limitations
- The paper states that the samples primarily consisted of non-Hispanic White women who had completed primary treatment for early-stage breast cancer, limiting generalizability to more diverse cancer populations.
- It states that the MBSR trial sample sizes were relatively small, limiting statistical power and analysis of specific racial or ethnic groups.
- It states that SF-36 Vitality was the only anchor used for responsiveness to change and AUC, had a different time frame than the FSI, and there is no criterion standard for fatigue responsiveness; it also notes that the 3-category MID approach may overestimate MIDs and that FSI-3 findings, including the cut-point and sensitivity to change, warrant replication.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 17 Not checked · 38 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“MIDs for fatigue measures have substantially varied in studies of patients with advanced disease or those undergoing cancer treatment [35–38] and have yet to be evaluated among post-treatment survivors.”
§ Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors > Background
What the sources say
- Not checked yetcites [35] Chan A, Yo TE, Wang XJ, Ng T, Chae J-W, Yeo HL et al (2018) Minimal clinically important difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for fatigue worsening in Asian breast cancer patients. J Pain Symptom Manage 55(3):992–7.e2. https://doi.org/10.1016/j.jpainsymman.2017.10.014 source
- Partly supportedcites [36] Yost KJ, Eton DT, Garcia SF, Cella D (2011) Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64(5):507–516 sourceExperimental — accuracy not yet measured
Our copy of Yost et al. (2011) does show variability in fatigue MID estimates, but only within this single study of advanced-stage patients on treatment: the Abstract Results give recommended T-score MID ranges of 2.5–4.5 (Fatigue-17) and 3.0–5.0 (Fatigue-7), Results 3.2 reports cross-sectional medians while 3.3 reports longitudinal medians 'considerably lower' (2.4 for Fatigue-7), and the Discussion states 'recommended T-score MIDs varied by PROMIS-Cancer scale'. The Discussion also only hedges that 'the MID may vary as a function of the level of impairment experienced by patients [36]' and calls for confirmation in other samples. What the source does not support is the claim's cross-study framing — it is not a review or pooling of multiple studies reporting that fatigue MIDs 'have substantially varied' across studies of advanced-disease or treated cancer patients; indeed it presents itself as the first estimate of MIDs for PROMIS T-scores. (LLM, conf=0.65)
- Not checked yetcites [37] Nordin Å, Taft C, Lundgren-Nilsson Å, Dencker A (2016) Minimal important differences for fatigue patient reported outcome measures—a systematic review. BMC Med Res Methodol 16(1):62. https://doi.org/10.1186/s12874-016-0167-6 source
- Not checked yetcites [38] Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F et al (2018) Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes 16(1):228. https://doi.org/10.1186/s12955-018-1055-z source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, although a 3-category approach (i.e., Worse, Same, or Better SF-36 Vitality scores) has commonly been used to determine MIDs and converges with distribution-based methods [68, 69], it may result in overestimation of MIDs.”
§ Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors > Discussion
What the sources say
- Not checked yetcites [68] Monahan PO, Boustani MA, Alder C, Galvin JE, Perkins AJ, Healey P et al (2012) Practical clinical tool to monitor dementia symptoms: the HABC-Monitor. Clin Interv Aging 7:143–157. https://doi.org/10.2147/cia.S30663 source
- Could not verifycites [69] Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T et al (2016) Patient Health Questionnaire Anxiety and Depression Scale: Initial validation in three clinical trials. Psychosom Med 78(6):716–727. https://doi.org/10.1097/psy.0000000000000322 sourceExperimental — accuracy not yet measured
Our copy of Kroenke et al. (2016) does use a 3-category change grouping (worse/same/improved, Methods > Statistical Analysis) but employs it to assess sensitivity to change of the PHQ-ADS via standardized response means, not to determine a minimal important difference; the SF-36 Vitality scale appears only as a baseline construct-validity measure (Methods > Measures). The paper's only MID-type estimates are distribution-based (1 or 2 SEM, Results > Psychometric Characteristics: MCID ~3-4 points for PHQ-ADS), and no passage states that a 3-category approach converges with distribution-based methods or that it may overestimate MIDs (searched: MID/MCID anchor-based vs distribution-based, overestimation, 3-category worse/same/better, SF-36 Vitality, global rating of change). Since our copy neither makes nor contradicts the attributed point, the claim cannot be verified against this source. (LLM, conf=0.65)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, these averages mask substantial individual differences in survivors’ fatigue trajectories that warrant further assessment with responsive measures [1, 4].”
§ Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors > Background
What the sources say
- Partly supportedcites [1] Bower JE (2014) Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597–609. https://doi.org/10.1038/nrclinonc.2014.127 sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) describe substantial inter-individual variability in fatigue and call for longitudinal studies to identify distinct trajectories. They support further assessment, but do not specify that the measures should be responsive to change; the claim’s reference to “responsive measures” is not supported by this copy. (LLM, conf=0.85)
- Not checked yetcites [4] Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE et al (2006) Fatigue in long-term breast carcinoma survivors. Cancer 106(4):751–758. https://doi.org/10.1002/cncr.21671 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Conversely, these measures showed large change in the trial of MBSR versus a waitlist control.”
§ Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within trials, all FSI measures yielded similar AUC values for differentiating significant fatigue at baseline using an SF-36 Vitality score ≤ 45 as the criterion (Table 5).”
§ Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors > Results > Area under the ROC (AUC)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 57 claims and to verify the 36 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Improvements in fatigue interference, severity, and levels exceeded the FSI MCIDs in the REVITALIZE arm, but not EUC [30].”
From Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue (2023) · cites this paper as [30]
Experimental — accuracy not yet measured
Citations
Cites
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362 · cited 3×
“3 is one criterion that can used to support the use of an anchor [39, 40], a threshold clearly met by the SF-36 Vitality scale for which baseline correlations with the FSI scales ranged from − 0.”
BackgroundMethodCancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666 · cited 3×
“Background Fatigue is a highly prevalent, persistent, debilitating problem in cancer survivors [1].”
BackgroundFatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.
Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.743 · Cited by 1,134 · cited 1×
“On average, fatigue tends to increase during cancer treatment and remit within 1 year following treatment [1, 33].”
BackgroundMustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., Mohr, D., Palesh, O. G., Peppone, L. J., Piper, B. F., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6914 · Cited by 932
Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00071-2 · Cited by 862
Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0344-y · Cited by 845 · cited 1×
“However, the International Society of Quality of Life Research has developed minimal standards for patient-centered outcomes, such as evidence of reliability, validity, responsiveness, and score interpretability [29].”
BackgroundKrebs, E. E., Lorenz, K. A., Bair, M. J., Damush, T. M., Wu, J., Sutherland, J. M., Asch, S. M., & Kroenke, K. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0981-1 · Cited by 782 · cited 3×
“The FSI-3 was adapted from the 3-item PEG which is an ultra-brief version of the Brief Pain Inventory (BPI) [55].”
MethodSelf-citation
Cited by
Reed, D. E., Stump, T. E., Monahan, P. O., & Kroenke, K. (2023) · Journal of Pain · doi:10.1016/j.jpain.2023.07.028 · Cited by 53
Self-citationWright, A. A., Poort, H., Tavormina, A., Schmiege, S. J., Matulonis, U. A., Campos, S. M., Liu, J. F., Slivjak, E. T., Gilmour, A. L., Salinger, J. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.020 · Cited by 12
Mosher, C. E., Lee, S., Addington, E. L., Park, S., Lewson, A. B., Snyder, S., Hirsh, A. T., Bricker, J. B., Miller, K. D., Ballinger, T. J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00965 · Cited by 18
“44 Although small pilots have hinted at the promise of ACT for reducing fatigue interference in patients with advanced cancer, 14,45 this study is the fi rst phase II trial of ACT in patients with cancer.”
Self-citationFatigue in Parkinson’s disease—A narrative review
Panigrahi, B., Pillai, K. S., Radhakrishnan, D. M., Rajan, R., & Srivastava, A. K. (2024) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_99_24 · Cited by 8
Sharma, S., Alexander, K. E., Green, T., Wu, M., & Bonner, A. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105032 · Cited by 4
Metadata
- Authors
- Mosher, C. E., Secinti, E., Johns, S. A., Kroenke, K., & Rogers, L. Q.
- Affiliations
- Indiana University – Purdue University Indianapolis (US)
- Regenstrief Institute (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Mosher, Catherine E.
- Venue
- Journal of Patient-Reported Outcomes
- Published
- 2022-07-23
- Volume
- 6
- Issue
- 1
- Pages
- 82-82
- ISSN
- 2509-8020 (ISSN-L)
- PMC
- PMC9308850
- OpenAlex
- W4286716094
- Cited by
- 14
- References
- 77
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 3 · 2023: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Patient-Reported Outcomes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
- Funders
- National Cancer Institute (R25CA117865, R01CA136859)
- Walther Cancer Foundation (0106–01)
- Indiana Clinical and Translational Sciences Institute (TR000163, TR000006)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- cancer survivorship, cancer-related fatigue, responsiveness to change, minimally important difference, psychometric properties, standardized response mean, area under the curve, fatigue analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. https://app.cochat.ai/papers/10.1186/s41687-022-00488-1
- The paper
- Mosher, C. E., Secinti, E., Johns, S. A., Kroenke, K., & Rogers, L. Q. (2022). Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. Journal of Patient-Reported Outcomes. https://doi.org/10.1186/s41687-022-00488-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.